Abstract library

542 results for "response criteria".
#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)
Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: PhD Paula Jimenez-Fonseca
Authors:
#667 Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors after Treatment with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) (unidimensional), Southwest Oncology Group (SWOG) solid tumor response criteria (bidimensional), and their modified variants (mRECIST/mSWOG) are used to assess treatment response in gastroenteropancreatic and thoracic neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Esther I Van Vliet
Authors:
#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Authors:
Keywords: sunitinib, PNET, Choi, RECIST
#1334 Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?
Introduction: There is no study to assess RECIST and Choi criteria in evaluating response of advanced GEP-NENs treated with sunitinb.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Yanji Luo
Authors:
#826 Correlation of Serum Chromogranin A Change with Radiographic Response in Patients with Non-Functioning Advanced Neuroendocrine Tumors
Introduction: Numerous studies have suggested that CgA determination may be useful for the diagnosis and follow-up of neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Yuejuan Cheng
Authors:
#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors:
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Authors:
Keywords: sunitinib, PNET, choi, recist
#642 Correlation Between Chromogranin A and RECIST in Neuroendocrine Tumors’ Treatment
Introduction: High Chromogranin A (CGA) levels have been associated with both tumor burden and the secretory activity of GEPNETs specially carcinoids.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: PhD MD Paula Jimenez Fonseca
Authors:
#1118 Is There an Additional Value of Somatostatin Receptor Subtype 2A Immunohistochemistry Over Somatostatin Receptor Scintigraphy in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
Introduction: It is not known whether tumoral somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) has additional value over OctreoScan® uptake in predicting response to PRRT in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: MD Roxanne Van Adrichem
Authors:
Keywords: sst2a
#1394 The Difficulties of Response Assessment After Peptide Receptor Radionucleotide Therapy (PRRT): An Unusual Case of Symptomatic Pseudoprogression
Introduction: In previous studies patient symptoms, biochemistry (including chromogranin A) and imaging using RECIST criteria have been used to assess tumour response to PRRT.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr Rahul Ladwa
Authors: